The bill amends the Public Health Code by adding section 17757c, which establishes regulations regarding the acquisition of 340B drugs by 340B entities and their authorized pharmacies. It prohibits manufacturers, wholesalers, and wholesale distributor-brokers from denying, restricting, or discriminating against these entities in their acquisition of 340B drugs. Additionally, it allows for the submission of reports by 340B entities and manufacturers starting July 1, 2026, detailing compliance with 340B program requirements and any significant price increases for prescription drugs, respectively.

The bill mandates that 340B entities submit annual reports that include their program recertification, community health needs assessments, and compliance affidavits, while manufacturers must report on prescription drugs that exceed a specified cost and have seen significant price increases. All reports will be made publicly accessible on the department's website. The bill also defines key terms related to the 340B program, ensuring clarity in its implementation. The enactment of this bill is contingent upon the passage of Senate Bill No. 95 of the 103rd Legislature.

Statutes affected:
Senate Introduced Bill: 333.1101, 333.25211